etoposide IV

In our model, CBD stimulated the cells, as confirmed by modulation of CB2 expression as well as changes in intracellular cAMP. Our results show that CBD in ranges between 5 [Formula: see text] to 50 [Formula: see text] does not significantly increase the amount of DNA double strand breaks in HepG2 cells compared to the control. However, we did observe a significant reduction in cell proliferation and a significant increase in intracellular cAMP levels following CBD treatment.

The patient received the first cycle of the chemotherapy regimen of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VAC/IE) and was discharged in a stable condition. This case emphasizes the need to consider EES in the differential diagnosis of nasal masses and highlights the necessity of molecular testing for EWSR1 rearrangements to confirm the diagnosis and guide therapy. Increased awareness and reporting are vital to enhancing diagnosis and management of this rare entity.

P2, N=31, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026

P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2

Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).

dexamethasone, ara-C, cisplatin (DHAP) was the most common salvage regimen (47.8%)...BCNU, etoposide, ara-C, melphalan (BEAM) was the most common conditioning regimen 91.9%...t-MN significantly contributes to NRM post-auto-HCT. Age at transplant is the primary risk factor, highlighting the need for vigilant monitoring and risk mitigation strategies.

P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended

P3, N=585, Completed, Shanghai Henlius Biotech | Active, not recruiting --> Completed

P2, N=22, Recruiting, RenJi Hospital | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.

Following multidisciplinary evaluation, the patient received systemic chemotherapy with etoposide and cisplatin, administered in four cycles under routine monitoring of hematologic and hepatic parameters. The case illustrates both the methodological steps required for accurate classification of duodenal NEC and the limitations of current treatment strategies. Our report contributes to the scarce data on duodenal bulb NEC and emphasizes the importance of early recognition, systematic diagnostic procedures, and multidisciplinary management to guide future practice.

P2, N=400, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.